This page shows the latest Waldenstrom's macroglobulinaemia news and features for those working in and with pharma, biotech and healthcare.
There was some positive news for Janssen, however, as Imbruvica received a positive recommendation to treat Waldenström's Macroglobulinaemia (WM) in adults who have had at least one prior therapy.
Draft guidance cites insufficient cost-effectiveness evidence for J&J’s drug. NICE has once again rejected Johnson &Johnson's Imbruvica (ibrutinib) for use on the NHS in England and Wales, ... Imbruvica is used to treat Waldenstrom's macroglobulinaemia
mantle cell lymphoma (MCL) and the treatment of Waldenström's macroglobulinaemia. ... AbbVie and J&J's drug also achieved partial or complete responses in 82% of patients, compared to 35% of the chemotherapy group.
Acalabrutinib is a Bruton's tyrosine kinase (Btk) inhibitor in the same class as Janssen/Pharmacyclics/Abbvie's Imbruvica (ibrutinib) drug for chronic lymphocytic leukaemia (CLL) and Waldenström's macroglobulinaemia, which ... This week it agreed a
as a treatment for chronic lymphocytic leukaemia (CLL) and Waldenström's macroglobulinaemia. ... Analysts have speculated that AZ's interest in Acerta could draw other possible suitors out of the shadows.
of Waldenström's macroglobulinaemia. ... Imbruvica is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor - licensed by Janssen from Pharmacyclics in 2011 in a deal valued at up to $975m.
More from news
Approximately 1 fully matching, plus 9 partially matching documents found.
We help communications teams to thrive under pressure. Here at fox&cat, we help all kinds of teams to fight all...